双歧杆菌三联活菌肠溶胶囊对便秘型肠易激综合征患者胃肠激素及氧化应激指标的影响

目的 研究双歧杆菌三联活菌肠溶胶囊对便秘型肠易激综合征（IBS C）患者症状评分、胃肠激素及氧化应激指标的影响。方法 选择2018年1 12月在上海市浦东新区周浦医院治疗的IBS C患者94例。用随机数表法分为对照组（n=47）和观察组（n=47），两组给予莫沙必利联合乳果糖治疗，观察组加用双歧杆菌三联活菌肠溶胶囊治疗，对照组加用安慰剂。比较两组的临床疗效、临床症状、胃肠激素、5 羟色胺（5 HT）及氧化应激指标。结果 观察组显效29例（61.70%），有效15例（31.91%），总有效率为93.62%，对照组仅为78.72%（P＜0.05）。治疗后两组临床症状评分明显下降，观察组腹胀腹痛、排便频率、大便性状和排便困难评分明显低于对照组（P＜0.05）。治疗后两组5 HT、丙二醛（MDA）和脂质过氧化物（LPO）水平明显下降，观察组5 HT、MDA和LPO水平低于对照组（P＜0.05）。治疗后两组胃肠激素水平均有所改善，观察组胃动素（MTL）水平高于对照组，血管活性肠肽（VIP）和生长抑素（SS）水平低于对照组（P＜0.05）。结论 双歧杆菌三联活菌胶囊联合乳果糖、莫沙必利治疗IBS C的疗效显著，能够明显改善患者的临床症状和胃肠激素水平，降低血浆5 HT水平，并减轻氧化应激反应，值得在临床推广应用。

Effects of Bifidobacterium triple viable enteric coated capsules on gastrointestinal hormones

Objective To study the effects of Bifidobacterium triple viable enteric coated capsules on symptoms score, gastrointestinal hormones and oxidative stress index in irritable bowel syndrome constipation（IBS C） patients. Methods A total of 94 patients with IBS C treated in our hospital from January 2018 to December 2018 were selected, and they were randomly divided into control group(n=47) and observation group(n=47). The two groups of patients were treated with mosapride in combination with lactulose, with observation group added with Bifidobacterium triple live enteric capsules, and control group added with placebo. The clinical efficacy, clinical symptoms, gastrointestinal hormones, 5 HT and oxidative stress were compared between two groups.Results In observation group, the treatment was markedly effective in 29 cases (61.70%), and effective in 15 cases (31.91%), with the total effective rate being 93.62%, and that of control group being 78.72%(P<0.05). After treatment, the scores of clinical symptoms in two groups decreased significantly. The scores of abdominal distension, abdominal pain, defecation frequency, stool characteristics and defecation difficulty in observation group were significantly lower than those in control group (P<0.05). After treatment, the levels of 5 HT, MDA and LPO in two groups also witnessed significance decrease. The levels of 5 HT, MDA and LPO in observation group were lower than those in control group (P<0.05). After treatment, the levels of gastrointestinal hormones in both groups were improved. The MTL level in observation group was higher than that in control group, and the levels of VIP and S S were lower than those in control group (P<0.05). Conclusion Bifidobacterium triple viable capsule combined with lactulose and Mosapride is effective in treatment of IBS C. It can significantly improve clinical symptoms and gastrointestinal hormone levels, reduce plasma 5 HT level and oxidative stress response, which makes it is worthy of clinical application.